Novartis’ early collaboration with NICE key to rapid response on Luxturna

In one of NICE’s fastest draft recommendations for a new therapy on the NHS, the HTA found gene therapy Luxturna from Novartis to be cost-effective to treat a rare genetic retinal disorder. Novartis’ offer of a discount early on helped speed the

Read the full 421 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE